US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kairos Pharma, Ltd.

0.6120

+0.03716.45%

Post-market: 0.62000.0080+1.31%19:55 EDT

Volume:793.68K

Turnover:473.02K

Market Cap:10.31M

PE:-2.19

High:0.6230

Open:0.5749

Low:0.5505

Close:0.5749

Loading ...

Overview Company News Filings

HC Wainwright Initiates Kairos Pharma at Buy With $12 Price Target

MT Newswires Live

Kairos Pharma: Promising Oncology Pipeline and Strategic Advancements Drive Buy Rating

Kairos Pharma: Promising Innovations in Cancer Drug Resistance and Immune Enhancement

Top Calls on Wall Street: Nvidia, Block, Lyft, Best Buy, RH, Zscaler, Ross Stores and More

Kairos Pharma Initiated at Buy by HC Wainwright & Co.

Kairos Pharma initiated with a Buy at H.C. Wainwright

Kairos Pharma, Ltd. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

Kairos Pharma Is Maintained at Buy by D. Boral Capital

BRIEF-Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of Env105 in Metastatic, Castration-Resistant Prostate Cancer

THOMSON REUTERS

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Kairos Pharma Initiated at Buy by Maxim Group

Kairos Pharma Ltd : Maxim Group Initiates Coverage With Buy Rating; Price Target $4

THOMSON REUTERS

Kairos Pharma initiated with a Buy at Maxim

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Kapa Gold Advances Blackhawk Project with New Permitting and Survey Initiatives

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma Is Maintained at Buy by D. Boral Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KAPA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KAPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","market":"US","secType":"STK","nameCN":"Kairos Pharma, Ltd.","latestPrice":0.612,"timestamp":1750276800000,"preClose":0.5749,"halted":0,"volume":793682,"hourTrading":{"tag":"盘后","latestPrice":0.62,"preClose":0.612,"latestTime":"19:55 EDT","volume":37505,"amount":22777.3611,"timestamp":1750290916595},"delay":0,"floatShares":6222871,"shares":16849306,"eps":-0.279234,"marketStatus":"Closed","change":0.0371,"latestTime":"06-18 16:00:00 EDT","open":0.5749,"high":0.623,"low":0.5505,"amount":473023.6779248,"amplitude":0.126109,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.279234,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750406400000},"marketStatusCode":5,"adr":0,"listingDate":1717992000000,"exchange":"NASDAQ","adjPreClose":0.5749,"preHourTrading":{"tag":"盘前","latestPrice":0.5933,"preClose":0.57,"latestTime":"09:28 EDT","volume":2926,"amount":1715.8207374,"timestamp":1750253302937},"postHourTrading":{"tag":"盘后","latestPrice":0.62,"preClose":0.612,"latestTime":"19:55 EDT","volume":37505,"amount":22777.3611,"timestamp":1750290916595},"volumeRatio":0.720597},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","floatShares":6222871,"roa":"-46.61%","roe":"-149.74%","lyrEps":-0.229208,"volumeRatio":0.720597,"shares":16849306,"dividePrice":0,"high":0.623,"amplitude":0.126109,"preClose":0.5749,"low":0.5505,"week52Low":0.4,"pbRate":"1.45","week52High":4,"institutionHeld":0,"latestPrice":0.612,"eps":-0.279234,"divideRate":0,"volume":793682,"delay":0,"ttmEps":-0.279234,"open":0.5749,"prevYearClose":1.52,"prevWeekClose":0.52,"prevMonthClose":0.61,"prevQuarterClose":0.9362,"fiveDayClose":0.4907,"twentyDayClose":0.59,"sixtyDayClose":0.952},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAPA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527625213","title":"HC Wainwright Initiates Kairos Pharma at Buy With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2527625213","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527625213?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:59","pubTimestamp":1744804785,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Kairos Pharma at Buy With $12 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2527939382","title":"Kairos Pharma: Promising Oncology Pipeline and Strategic Advancements Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2527939382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527939382?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:16","pubTimestamp":1744798612,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kairos Pharma, Ltd. (KAPA – Research Report) and keeping the price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kairos-pharma-promising-oncology-pipeline-and-strategic-advancements-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kairos-pharma-promising-oncology-pipeline-and-strategic-advancements-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2524296998","title":"Kairos Pharma: Promising Innovations in Cancer Drug Resistance and Immune Enhancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2524296998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524296998?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:05","pubTimestamp":1743699915,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. (KAPA) has received a new Buy rating, initiated by H.C. Wainwright analyst, Joseph Pantginis. Joseph Pantginis has given his Bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kairos-pharma-promising-innovations-in-cancer-drug-resistance-and-immune-enhancement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kairos-pharma-promising-innovations-in-cancer-drug-resistance-and-immune-enhancement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","BK4139","KAPA"],"gpt_icon":0},{"id":"1105265075","title":"Top Calls on Wall Street: Nvidia, Block, Lyft, Best Buy, RH, Zscaler, Ross Stores and More","url":"https://stock-news.laohu8.com/highlight/detail?id=1105265075","media":"The Fly","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105265075?lang=en_us&edition=fundamental","pubTime":"2025-04-03 23:30","pubTimestamp":1743694200,"startTime":"0","endTime":"0","summary":"The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades:Morga","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thefly.com/landingPageNews.php?id=4099879&headline=XYZ;ZS;ROST;TJX;FAST;NVDA;LYFT;RXST;RH;BBY;SNDK;ESI;TALK;EQBK;KAPA-Block-upgraded-Nvidia-downgraded-Wall-Streets-top-analyst-calls&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1649979459173","symbols":["FAST","NVDA","ROST","LYFT","TJX","ZS","ESI","SNDK","EQBK","RH","KAPA","RXST","TALK","XYZ","BBY"],"gpt_icon":1},{"id":"2524123770","title":"Kairos Pharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524123770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524123770?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:01","pubTimestamp":1743678060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 07:01 ET (11:01 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA","KAIR"],"gpt_icon":0},{"id":"2524234948","title":"Kairos Pharma initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2524234948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524234948?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:16","pubTimestamp":1743675383,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could unlock the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAIR","KAPA"],"gpt_icon":0},{"id":"2524391882","title":"Kairos Pharma, Ltd. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2524391882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524391882?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:03","pubTimestamp":1743674628,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nAZN3NMNXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2523499149","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2523499149","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523499149?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:39","pubTimestamp":1743424740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 08:39 ET (12:39 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2523917211","title":"BRIEF-Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917211","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917211?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:13","pubTimestamp":1743419608,"startTime":"0","endTime":"0","summary":"BRIEF-Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate CancerMarch 31 (Reuters) - Kairos Pharma ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA5JVFJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2523452912","title":"Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of Env105 in Metastatic, Castration-Resistant Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523452912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523452912?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA5JVFJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2522531125","title":"Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2522531125","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522531125?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"LOS ANGELES, March 27, 2025----Kairos Pharma, Ltd. , a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in future events.March 12, 2025 – Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, \"Novel GITR Agonist KROS 101: A Dual Approach to Boost T Cell Immunity and Alter the Tumor Microenvironment\". March 17 to 19 – Participated in the BIO Europe conference in Milan, Italy. April 29 to May 1 – Kairos is slated to participate at the Fierce Pharma Engage Business Development and Licensing Meeting in San Diego. This press release contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as \"may,\" \"should,\" \"expects,\" \"anticipates,\" \"contemplates,\" \"estimates,\" \"believes,\" \"plans,\" \"projected,\" \"predicts,\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-ltd-highlights-participation-200500406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","KAPA","KAIR"],"gpt_icon":0},{"id":"2522824589","title":"Kairos Pharma Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2522824589","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522824589?lang=en_us&edition=fundamental","pubTime":"2025-03-28 00:05","pubTimestamp":1743091500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 12:05 ET (16:05 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAIR","KAPA"],"gpt_icon":0},{"id":"2522374201","title":"Kairos Pharma Ltd : Maxim Group Initiates Coverage With Buy Rating; Price Target $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374201?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:53","pubTimestamp":1743076389,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA11O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2522437113","title":"Kairos Pharma initiated with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2522437113","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522437113?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:40","pubTimestamp":1743075611,"startTime":"0","endTime":"0","summary":"Maxim analyst Jason McCarthy initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $4 price target Published first on TheFly – the ultim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-initiated-with-a-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-initiated-with-a-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","KAPA","BK4139"],"gpt_icon":0},{"id":"2521952204","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2521952204","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521952204?lang=en_us&edition=fundamental","pubTime":"2025-03-21 03:49","pubTimestamp":1742500140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 15:49 ET (19:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2520100458","title":"Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520100458","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520100458?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:30","pubTimestamp":1742470200,"startTime":"0","endTime":"0","summary":"LOS ANGELES, March 20, 2025----Kairos Pharma, Ltd. , a clinical-stage biopharmaceutical company, announces a peer-reviewed publication highlighting a potentially significant breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer  patients. Recent findings published in Drug Resistance Updates highlight the critical role of CD105  in mediating resistance to osimertinib, a frontline treatment for EGFR-mutant NSCLC. The study, titled, \"CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer,\" demonstrated that CD105 expression is upregulated as a mechanism of therapy resistance, correlating with poor prognosis in patients.Based in Los Angeles, California, Kairos Pharma Ltd.  is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-ltd-announces-peer-113000085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KAPA","KAIR","BK4139"],"gpt_icon":0},{"id":"2517940740","title":"Kapa Gold Advances Blackhawk Project with New Permitting and Survey Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2517940740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517940740?lang=en_us&edition=fundamental","pubTime":"2025-03-06 02:12","pubTimestamp":1741198334,"startTime":"0","endTime":"0","summary":"KAPA Gold Inc ( ($TSE:KAPA) ) has provided an announcement. Kapa Gold Inc. has announced updates on its Blackhawk Gold Project, highlighting the in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kapa-gold-advances-blackhawk-project-with-new-permitting-and-survey-initiatives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kapa-gold-advances-blackhawk-project-with-new-permitting-and-survey-initiatives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2514237837","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2514237837","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514237837?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:13","pubTimestamp":1740575580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 08:13 ET (13:13 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2514839973","title":"Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2514839973","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514839973?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"LOS ANGELES, February 26, 2025----Kairos Pharma, Ltd. , a clinical-stage biopharmaceutical company, announced that the company presented preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research Immuno-Oncology  conference held in Los Angeles from February 23-26, 2025. The data highlighted positive preclinical outcomes with the Company’s glucocorticoid-induced tumor necrosis factor receptor  agonist KROS101 in melanoma and glioblastoma as well as its peptide inhibitor for macrophages KROS 401 in glioma animal models.The second presentation, titled, \"Targeting M2 macrophage polarization: The anti-tumor effects of IL-4/IL-13 blocking peptide and iron oxide nanoparticles,\" demonstrated the Company’s peptide inhibitor KROS 401 may effectively reprogram macrophages – types of white blood cell of the innate immune system that engulf and digest pathogens, such as cancer cells, microbes, cellular debris and foreign substances – ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-presents-preclinical-data-120000742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KROS","KAIR","BK4139","KAPA"],"gpt_icon":0},{"id":"2512195122","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512195122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512195122?lang=en_us&edition=fundamental","pubTime":"2025-02-19 02:48","pubTimestamp":1739904480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 13:48 ET (18:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":55,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAPA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAPA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1743739200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAPA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAPA","date":"2025-06-17","current":-2.57116,"percent":0.968085,"low":-25.607053,"twenty":-8.603969,"median":-6.749132,"eighty":-4.767574,"high":-2.140651,"avg":-6.925609,"sd":3.334257,"marketCap":9107049},"quantilePoints":[{"date":"2024-09-13","current":-25.607053,"twenty":-25.607053,"median":-25.607053,"eighty":-25.607053,"marketCap":51367748},{"date":"2024-09-20","current":-14.59602,"twenty":-25.607053,"median":-16.196461,"eighty":-14.724055,"marketCap":29279616},{"date":"2024-09-27","current":-10.594918,"twenty":-16.644584,"median":-14.59602,"eighty":-12.803526,"marketCap":21253405},{"date":"2024-10-04","current":-8.706398,"twenty":-15.748337,"median":-12.835535,"eighty":-9.858715,"marketCap":17465034},{"date":"2024-10-11","current":-9.410592,"twenty":-14.724055,"median":-10.594918,"eighty":-8.706398,"marketCap":18877647},{"date":"2024-10-18","current":-9.410592,"twenty":-14.59602,"median":-9.890724,"eighty":-9.026486,"marketCap":18877647},{"date":"2024-10-25","current":-9.602645,"twenty":-14.019861,"median":-9.73068,"eighty":-9.026486,"marketCap":19262905},{"date":"2024-10-31","current":-8.64238,"twenty":-13.098007,"median":-9.602645,"eighty":-8.947104,"marketCap":17336614},{"date":"2024-11-08","current":-8.770415,"twenty":-12.81633,"median":-9.464686,"eighty":-8.64238,"marketCap":17593453},{"date":"2024-11-15","current":-13.158824,"twenty":-13.152678,"median":-9.474609,"eighty":-8.64238,"marketCap":26396601},{"date":"2024-11-22","current":-7.030345,"twenty":-12.924264,"median":-9.410592,"eighty":-8.578362,"marketCap":19270177},{"date":"2024-11-29","current":-7.217821,"twenty":-12.829133,"median":-9.282556,"eighty":-8.469532,"marketCap":19784048},{"date":"2024-12-06","current":-6.608525,"twenty":-12.265778,"median":-9.026486,"eighty":-7.967725,"marketCap":18113966},{"date":"2024-12-13","current":-8.061463,"twenty":-11.119862,"median":-8.738406,"eighty":-7.667763,"marketCap":22096470},{"date":"2024-12-20","current":-7.920856,"twenty":-10.268428,"median":-8.706398,"eighty":-7.780249,"marketCap":21711066},{"date":"2024-12-27","current":-7.827118,"twenty":-9.999554,"median":-8.64238,"eighty":-7.780249,"marketCap":21454130},{"date":"2025-01-03","current":-7.170953,"twenty":-9.909929,"median":-8.578362,"eighty":-7.46154,"marketCap":19655581},{"date":"2025-01-10","current":-4.827504,"twenty":-9.858715,"median":-8.578362,"eighty":-7.311559,"marketCap":13232188},{"date":"2025-01-17","current":-8.295808,"twenty":-9.858715,"median":-8.530349,"eighty":-7.261949,"marketCap":22738809},{"date":"2025-01-24","current":-7.311559,"twenty":-9.756287,"median":-8.373067,"eighty":-7.264142,"marketCap":20040984},{"date":"2025-01-31","current":-6.936607,"twenty":-9.73068,"median":-8.108332,"eighty":-7.170953,"marketCap":19013241},{"date":"2025-02-07","current":-6.749132,"twenty":-9.628252,"median":-8.036517,"eighty":-7.161579,"marketCap":18499370},{"date":"2025-02-14","current":-6.796001,"twenty":-9.602645,"median":-7.967725,"eighty":-7.030345,"marketCap":18627838},{"date":"2025-02-21","current":-6.233573,"twenty":-9.526207,"median":-7.967725,"eighty":-7.030345,"marketCap":17086224},{"date":"2025-02-28","current":-5.671145,"twenty":-9.474865,"median":-7.897422,"eighty":-6.869431,"marketCap":15544609},{"date":"2025-03-07","current":-5.198227,"twenty":-9.462702,"median":-7.803684,"eighty":-6.730384,"marketCap":14248340},{"date":"2025-03-14","current":-4.773372,"twenty":-9.428261,"median":-7.780249,"eighty":-6.44917,"marketCap":13083812},{"date":"2025-03-21","current":-4.898329,"twenty":-9.410592,"median":-7.639642,"eighty":-6.289816,"marketCap":13426320},{"date":"2025-03-28","current":-4.848346,"twenty":-9.33377,"median":-7.452166,"eighty":-6.092966,"marketCap":13289317},{"date":"2025-04-04","current":-4.698397,"twenty":-9.282556,"median":-7.358428,"eighty":-5.577408,"marketCap":12878307},{"date":"2025-04-11","current":-4.948312,"twenty":-9.244146,"median":-7.311559,"eighty":-5.297393,"marketCap":13563323},{"date":"2025-04-17","current":-4.775903,"twenty":-9.141718,"median":-7.263319,"eighty":-5.121191,"marketCap":12431676},{"date":"2025-04-25","current":-5.470376,"twenty":-9.018804,"median":-7.217821,"eighty":-5.172643,"marketCap":14239390},{"date":"2025-05-02","current":-5.034285,"twenty":-8.912535,"median":-7.170953,"eighty":-5.172643,"marketCap":13104245},{"date":"2025-05-09","current":-4.841892,"twenty":-8.744808,"median":-7.124084,"eighty":-5.140524,"marketCap":12603446},{"date":"2025-05-16","current":-2.898471,"twenty":-8.706398,"median":-7.030345,"eighty":-5.053706,"marketCap":10266383},{"date":"2025-05-23","current":-2.643971,"twenty":-8.706398,"median":-7.030345,"eighty":-4.968305,"marketCap":9364944},{"date":"2025-05-30","current":-2.626341,"twenty":-8.693594,"median":-6.936607,"eighty":-4.902727,"marketCap":9302501},{"date":"2025-06-06","current":-2.390394,"twenty":-8.64238,"median":-6.865004,"eighty":-4.843183,"marketCap":8466776},{"date":"2025-06-13","current":-2.711492,"twenty":-8.629576,"median":-6.796001,"eighty":-4.780395,"marketCap":9604104},{"date":"2025-06-17","current":-2.57116,"twenty":-8.603969,"median":-6.749132,"eighty":-4.767574,"marketCap":9107049}],"updateTime":1750288701554}}}